Celcuity Inc (CELC) Stock Price, Quote & News

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...

Industry: Biotechnology

Sector: Healthcare

Phone: 763 392 0767

Website: www.celcuity.com

Address:

16305 36th Avenue North, Suite 100, Minneapolis, United States

CharlieeMungerTWITS Apr. 24 at 7:18 PM

$CELC fudge I only got a partial fill on my order at 113. Oh well

0 · Reply

LabMan Apr. 24 at 2:30 AM

$KZIA $CELC Upside explanation condensed into single (longish) paragraph" The Kazia drug paxalisib is one of only 2 drugs in development in the Pi3K mTOR, MULTI isofoym ( there are 4 isoforms), drug class. The other is Celcuity. The Pi3K pathway controls human growth and function. Errant enzymes in the Pi3K pathway strongly contribute to cancer and half of other human diseases in our life. Pi3K drugs, especially single isoform Pi3K alpha isoform - that are safe, help to inhibit ( means repair) this pathway and fight cancer. Celcuity explains perfectly that only 4 isoforms Pi3K mTOR drugs eg Kazia & Celcuity are highly more effective, than Pi3K alpha alone. Only paxalisib enters the brain - head to head with Celcuity, will be of much interest, at a later time. So apparent huge potential here, with this company. " Both companies, in fact.

1 · Reply

Johnny_Lever Apr. 23 at 11:57 PM

$CELC Just when you think you've seen the light at the end of a long sideways channel, BAM!

0 · Reply

CharlieeMungerTWITS Apr. 23 at 9:57 PM

$CELC hit me 88 @ 113

0 · Reply

CharlieeMungerTWITS Apr. 23 at 8:35 PM

$CELC loaded more

0 · Reply

CharlieeMungerTWITS Apr. 23 at 8:33 PM

$CELC cycle is here. $110 to $125. Rinse repeat and hold a core

0 · Reply

Dark_Horse_Investments Apr. 23 at 5:13 PM

$CELC opportunity to add a little...

1 · Reply

Florestan Apr. 22 at 12:09 PM

$CELC if you're confused as to why some biotechs go down after data spike, and some just keep going up, you should REALLY figure that out first before touching bios.

0 · Reply

BIOTECH_GURU Apr. 22 at 2:18 AM

$CELC bang! 💥

0 · Reply

Jonita Apr. 21 at 5:29 PM

$CELC in in in

0 · Reply

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 18, 2026, 8:00 AM EDT - 5 weeks ago

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

Mar 9, 2026, 5:42 PM EDT - 6 weeks ago

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

Feb 25, 2026, 4:01 PM EST - 2 months ago

Celcuity To Participate in Upcoming Investor Conferences

Feb 12, 2026, 4:05 PM EST - 2 months ago

Celcuity Appoints Charles Romp to its Board of Directors

Feb 4, 2026, 7:05 AM EST - 2 months ago

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 22, 2026, 10:26 AM EST - 3 months ago

These 20 stocks are strong choices for momentum investors

BE COGT FBYD FRGE INBX KOD LITE

Jan 20, 2026, 7:30 AM EST - 3 months ago

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Dec 11, 2025, 2:35 PM EST - 4 months ago

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Nov 26, 2025, 4:05 PM EST - 5 months ago

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Nov 26, 2025, 7:05 AM EST - 5 months ago

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

Nov 17, 2025, 4:05 PM EST - 5 months ago

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Nov 12, 2025, 4:01 PM EST - 5 months ago

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:05 AM EST - 6 months ago

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Nov 4, 2025, 7:05 AM EST - 6 months ago

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

Oct 20, 2025, 9:42 AM EDT - 6 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CRMD RANI RAPT

Oct 18, 2025, 4:30 AM EDT - 6 months ago

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Oct 18, 2025, 4:30 AM EDT - 6 months ago

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Oct 18, 2025, 4:30 AM EDT - 6 months ago

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Sep 22, 2025, 9:15 AM EDT - 7 months ago

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Sep 9, 2025, 4:01 PM EDT - 8 months ago

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Aug 27, 2025, 4:05 PM EDT - 8 months ago

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program

Aug 14, 2025, 4:01 PM EDT - 9 months ago

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:05 AM EDT - 9 months ago

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Jul 30, 2025, 6:30 AM EDT - 9 months ago

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

Jul 29, 2025, 6:40 AM EDT - 9 months ago

Celcuity: What's Happening With CELC Stock?

Jul 28, 2025, 4:02 PM EDT - 9 months ago

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Jul 28, 2025, 3:02 PM EDT - 9 months ago

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success

Jul 28, 2025, 7:49 AM EDT - 9 months ago

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study

Jul 28, 2025, 7:00 AM EDT - 9 months ago

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Jul 25, 2025, 4:05 PM EDT - 9 months ago

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Jul 24, 2025, 4:01 PM EDT - 9 months ago

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Jul 14, 2025, 7:05 AM EDT - 10 months ago

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

Jun 30, 2025, 7:05 AM EDT - 10 months ago

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

May 21, 2025, 7:05 AM EDT - 1 year ago

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

May 14, 2025, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

Apr 1, 2025, 7:05 AM EDT - 1 year ago

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Feb 25, 2025, 7:05 AM EST - 1 year ago

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

Dec 11, 2024, 7:05 AM EST - 1 year ago

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Nov 14, 2024, 4:01 PM EST - 1 year ago

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

Nov 12, 2024, 7:05 AM EST - 1 year ago

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

Nov 7, 2024, 7:05 AM EST - 1 year ago

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

Aug 7, 2024, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

Jun 3, 2024, 4:01 PM EDT - 2 years ago

Celcuity To Participate in Jefferies Global Healthcare Conference

May 30, 2024, 7:36 AM EDT - 2 years ago

Celcuity Announces Pricing of Underwritten Common Stock Offering

May 30, 2024, 7:00 AM EDT - 2 years ago

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

CharlieeMungerTWITS Apr. 24 at 7:18 PM

$CELC fudge I only got a partial fill on my order at 113. Oh well

0 · Reply

LabMan Apr. 24 at 2:30 AM

1 · Reply

Johnny_Lever Apr. 23 at 11:57 PM

$CELC Just when you think you've seen the light at the end of a long sideways channel, BAM!

0 · Reply

CharlieeMungerTWITS Apr. 23 at 9:57 PM

$CELC hit me 88 @ 113

0 · Reply

CharlieeMungerTWITS Apr. 23 at 8:35 PM

$CELC loaded more

0 · Reply

CharlieeMungerTWITS Apr. 23 at 8:33 PM

$CELC cycle is here. $110 to $125. Rinse repeat and hold a core

0 · Reply

Dark_Horse_Investments Apr. 23 at 5:13 PM

$CELC opportunity to add a little...

1 · Reply

Florestan Apr. 22 at 12:09 PM

$CELC if you're confused as to why some biotechs go down after data spike, and some just keep going up, you should REALLY figure that out first before touching bios.

0 · Reply

BIOTECH_GURU Apr. 22 at 2:18 AM

$CELC bang! 💥

0 · Reply

Jonita Apr. 21 at 5:29 PM

$CELC in in in

0 · Reply

DipinDipout Apr. 21 at 3:24 PM

$CELC Any thoughts on early potential timelines of PDUFA or will in drop as planned in July?

1 · Reply

GorillaTrades Apr. 17 at 7:03 PM

Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Stoke Therapeutics $STOK +6.6%, NVIDIA $NVDA +6.5%, and Celcuity $CELC +4.6%

0 · Reply

West_Bale Apr. 17 at 4:47 PM

$CELC Can we assume the PIK3CA mutant cohort has a longer PFS? So the report is much later than the wild type. Or is it because it took longer to recruit the number of patients?

0 · Reply

DipinDipout Apr. 17 at 4:35 PM

$CELC @Quantumup do you work for Relay or are you on the wrong board trying to drive it…this is for CELC so let’s keep it to that!

0 · Reply

Quantumup Apr. 17 at 1:05 PM

BofA⬆️ $RLAY's PT and said: Previewing upcoming data in rare disease with unmet need; reit Buy, PO to $21—Higher PO on higher conviction for expanding opportunity $PVLA TARA $CELC RHHBY NVS LLY AZN BofA added—We preview initial clinical data for Relay's zovegalisib in vascular malformation (VM), ahead of late-breaking presentation at ISSVA (May 20). We believe the drug could differentiate from other treatments for this disease. This leads us to raise our PO to $21 (from $15) after adding risk-adjusted VM forecast ($1BN+ nominal) in our model. RLAY has had a strong run YTD (+83% vs +12% XBI) amid upcoming catalysts and peer group consolidation. Even with growing attention around the upcoming data, we think RLAY's ongoing development for breast cancer (2L) and cash position support today's valuation. We see further upside potential from: 1) data further supporting zovega as a leading treatment for VM, 2) the drug expanding into earlier-stage breast cancer. Reiterate Buy.

1 · Reply

LabMan Apr. 17 at 3:07 AM

$CELC $KZIA Background-Brian Sullivan CEO suggested gedatolisib is unique drug, designed to inhibit (repair) all 4 isoforms of the PI3K family. The whole issue is that paxalisib is a near identical drug, but with ability to cross the brain barrier. (unlike gedatolisib). Brain metastases mean cancer moves to the brain/ death in 10% to 35% of all cancers. Pax and some exceptional recent pre clinic discoveries, have since been highlighted to the Mr Sullivan. Paxalisib has been tested in 450 patients over 15 sponsored FDA early to mid-trials. Principal investigators Harvard, Dana Farber, John Hopkins, MSK & other top 10 hospitals. Celcuity & Kazia each paid $5M - gedatolisib in 2021 from Pifzer -and paxalisib 10 years ago, from Genentech. Immediately Brian Sullivan commenced studies in drug combo, while paxalisib endured disappointment as later discoveries, show cancer escapes monotherapy PI3K treatment. Now paxalisib in early combo studies. The float size? Kzia 4 years behind? Brain?

0 · Reply

CharlieeMungerTWITS Apr. 17 at 2:47 AM

$CELC Topline Phase 3 VIKTORIA-1 data (PIK3CA-mutated cohort) is expected in mid-2026. They didn’t give a hard date, but “mid-2026” typically points to late Q2 into early Q3 2026 — so think roughly June–July timeframe. Given that: • Their PDUFA is July 17, 2026 • The data is expected around the same window This sets up a tight catalyst cluster: trial readout + FDA decision potentially overlapping.

0 · Reply

cd1234 Apr. 16 at 4:27 PM

$CELC waiting on the mutant data from VIKTORIA-1

1 · Reply

LabMan Apr. 14 at 12:44 PM

$CELC Kazia's PI3K mTOR brain penetrant drug was developed by Genentech. Of high signifance, & unlike gedatolisib, paxalisib crosses through to the BBB. Here is specific evidence of the success of paxalisib in a 2023 FDA Clinical brain mets trial, undertaken initially at Memorial Sloan Kettering in 2023. Note the comments of leading researcher, before his move to Washingtom Uni. QUOTE "In our previous work, we learned that brain metastases with activating PI3K pathway mutations are more resistant to radiation therapy- thus have worse disease control. Paxalisib is therefore a logical choice of drug and, combined with radiotherapy, it may help overcome this resistance," J Yang, MD, PhD, director of metastatic disease Washington, told Targeted OncologyTM. "I think the FDA, by expediting the development of this combination, recognizes the need for more effective drug/ therapy combination treatments, importance of precision radiation oncology strategies based on tumor molecular profiling."

2 · Reply

LabMan Apr. 14 at 10:50 AM

$KZIA $CELU $KZIA $CELC Despite the float size disparity between both PI3K mTOR drug companies - comparisons are valid. Celcuity - IV administration, has lodged an NDA. KZIA (Phase 1). Only the latter drug paxalisib however, can cross the blood brain barrier. A compelling factor, due to occurrence of brain metastasis in about 25% of all cancers, which results in patient death. The PI3K pathway also contributes to major human neurological diseases such as Parkinsons and Alzheimer's. Generally unknown to Celcuity market participants, is the view that overdue PIK3CA mutant cohort results, in VIKTORIA 2, have been delayed due to extended MOS. It is likely, that ongoing data survival maturation, has very positively influenced the timing of the final topline report. The earlier VIKTORIA 1 in non PI3K breast cancer (wild type) highlights the revolution, this class of drug is bringing to cancer treatment.

2 · Reply

CharlieeMungerTWITS Apr. 13 at 10:57 PM

$CELC July 17th pdufa!!! this one is going to bang hard. Good cash, good share count, awesome drug @GreggTwits cleanest (no warrants + less aggressive dilution pattern) Why it stands out: • Float: ~30M (low) • Retail-accessible float: ~9–12M • Institutional ownership: moderate (not fully locked) • Catalyst: July 17, 2026 PDUFA • Strong Phase 3 data → real narrative fuel This is the ideal storm: • Tight float • Enough retail control • Clear, binary catalyst • Prior history of big % moves

1 · Reply

moneybag888 Apr. 13 at 10:55 PM

$CELC $RVMD

0 · Reply

Market Cap	5.49B
Revenue (ttm)	0.00
Net Income (ttm)	-177.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.26

Volume	1,070,800
Avg Vol	699,202
Day's Range	N/A - N/A
Shares Out	48.34M
Stochastic %K	67%
Beta	0.41
Analysts	Strong Sell
Price Target	$128.60